Natalizumab for the treatment of relapsing multiple sclerosis by Rudick, Richard A & Panzara, Michael A
© 2008 Dove Medical Press Limited.   All rights reserved
Biologics: Targets & Therapy 2008:2(2) 189–199 189
REVIEW
Natalizumab for the treatment of relapsing 
multiple sclerosis
Richard A Rudick1
Michael A Panzara2
1Cleveland Clinic Foundation, 
Cleveland, OH, USA; 2Biogen Idec, 
Inc., Cambridge, MA, USA
Correspondence: Richard A Rudick
Cleveland Clinic Foundation, 9500 Euclid 
Avenue, Area U100, Cleveland, OH 44195, 
USA
Tel +1 216 445 1915
Fax +1 216 445 5192
Email rudickr@ccf.org
Abstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with 
relapsing multiple sclerosis (MS), based on demonstrated efﬁ  cacy in the pivotal AFFIRM study 
(N = 942). Natalizumab monotherapy reduced risk of disability progression by 42%–54% and 
annualized relapse rate by 68% during a period of 2 years. Natalizumab was also associated with 
signiﬁ  cant reductions in number of T2-hyperintense, gadolinium-enhancing, and T1-hypointense 
lesions and in volume of T2-hyperintense lesions (all p  0.001) on magnetic resonance imaging. 
Furthermore, natalizumab-treated patients in AFFIRM experienced signiﬁ  cant improvements 
from baseline in the physical and mental components of the Short Form-36 (p  0.01) and a 
35% reduction in risk of clinically signiﬁ  cant vision loss (p = 0.008 vs placebo). Natalizumab 
was well tolerated in phase 3 studies. Common adverse events were generally mild and included 
headache, fatigue, urinary tract infections, and arthralgia. Serious adverse events were similar 
between treatment groups. The incidence of serious hypersensitivity reactions associated with 
natalizumab was 1%. Progressive multifocal leukoencephalopathy was a rare complication 
of treatment, observed in 2 patients with MS who received natalizumab plus interferon β-1a. 
The robust clinical beneﬁ  ts of natalizumab, including beneﬁ  ts on patient-reported quality of 
life, make it an important addition to disease-modifying therapies available to patients with 
relapsing MS.
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Introduction
Multiple sclerosis (MS) is a chronic, inﬂ  ammatory disease of the central nervous system 
(CNS). The disease is characterized by focal areas of demyelination and axonal loss 
that may be manifested as sensory disturbances, unilateral optic neuritis, diplopia, 
limb weakness, clumsiness, gait ataxia, neuropsychological impairment, sexual and 
bladder dysfunction, pain, fatigue, and spasticity (Noseworthy et al 2000). Although 
the pathogenesis of MS is not completely understood, it is believed that interactions 
between adhesion molecules on activated leukocytes and their receptors on endothelial 
cells of the vessel wall promote leukocyte migration across the blood-brain barrier. 
Once in the CNS, leukocytes may reactivate and promote recruitment of a second wave 
of leukocytes into the CNS. This reaction in turn promotes an inﬂ  ammatory cascade 
that causes demyelination and axonal loss (ffrench-Constant 1994).
Natalizumab (Tysabri®; Biogen Idec, Inc., Cambridge, MA, USA and Elan Phar-
maceuticals, Inc., San Francisco, CA, USA), a humanized monoclonal antibody to 
the α4-subunit of α4β1-integrin (expressed on the surface of all leukocytes except 
neutrophils), is the ﬁ  rst selective adhesion molecule inhibitor available for the treatment 
of MS. By binding to α4-integrin, natalizumab inhibits the α4-mediated adhesion of 
leukocytes to the vascular cell adhesion molecule-1 receptor expressed on vascular 
endothelial cells, preventing leukocyte recruitment into the CNS and subsequent inﬂ  am-
matory activity. Natalizumab has also been postulated to inhibit leukocyte priming Biologics: Targets & Therapy 2008:2(2) 190
Rudick and Panzara
and lymphocyte apoptosis by inhibiting interactions between 
α4-integrin and its ligands (Rudick and Sandrock 2004).
Two randomized, double-blind, placebo-controlled 
studies, AFFIRM (Natalizumab Safety and Efficacy in 
Relapsing-Remitting Multiple Sclerosis) and SENTINEL 
(Safety and Efﬁ  cacy of Natalizumab in Combination With 
Interferon Beta-1a in Patients With Relapsing-Remitting 
Multiple Sclerosis), were conducted to evaluate the efﬁ  cacy 
and safety of natalizumab alone (AFFIRM) or in combination 
with interferon β-1a (SENTINEL) in patients with relapsing 
MS (Polman et al 2006; Rudick et al 2006). The primary 
endpoints in both studies were the rate of clinical relapses at 
1 year and the cumulative probability of disability progression 
sustained for 12 weeks at 2 years. Predeﬁ  ned secondary 
and tertiary endpoints included the effect of natalizumab 
on magnetic resonance imaging (MRI) outcomes, health-
related quality of life (HRQoL), and visual function. This 
article reviews the available data describing the effects of 
natalizumab on these clinical parameters. In addition, the 
safety and tolerability proﬁ  le of natalizumab is discussed.
Efﬁ  cacy of natalizumab in pivotal 
studies
The efﬁ  cacy of natalizumab monotherapy was evaluated in 
the AFFIRM study (Polman et al 2006). Key inclusion criteria 
were similar to pivotal studies of disease-modifying therapies 
(DMTs) for MS (IFNB Study Group 1993; Jacobs et al 
1996; Johnson et al 1995; PRISMS Study Group 1998) and 
included a diagnosis of relapsing MS according to McDonald 
criteria (McDonald et al 2001), Expanded Disability Status 
Scale (EDSS) scores from 0 to 5.0, MRI lesions consistent 
with MS, and at least 1 medically documented relapse 
within the 12 months before randomization. Patients were 
excluded from the study if they had progressive forms of MS 
(Lublin and Reingold 1996); had a relapse within 50 days 
of study drug administration; or were treated with interferon 
β, glatiramer acetate, or both for more than 6 months. 
Enrolled patients were randomized in a 2:1 ratio to receive 
an intravenous infusion of natalizumab 300 mg or placebo 
every 4 weeks for up to 116 weeks (Polman et al 2006).
The SENTINEL study evaluated the efﬁ  cacy of natali-
zumab added to intramuscular interferon β-1a (Avonex®; 
Biogen Idec, Inc., Cambridge, MA, USA). In addition to 
the key inclusion criteria in the AFFIRM study, patients 
entering the SENTINEL study had received treatment with 
intramuscular interferon β-1a for at least 12 months before 
randomization and had at least 1 relapse in the prior year 
despite interferon therapy. Patients with progressive forms 
of MS (Lublin and Reingold 1996), those who experienced 
a relapse within 50 days before study drug administration, 
or those who received treatment with an approved DMT 
other than intramuscular interferon β-1a once weekly within 
the 12 months before randomization were excluded from 
the study. Enrolled patients were randomized to receive 
an intravenous infusion of natalizumab 300 mg or placebo 
every 4 weeks in addition to an intramuscular injection of 
interferon β-1a (30 μg) once weekly for up to 116 weeks 
(Rudick et al 2006).
Primary endpoints in both studies were the rate of clini-
cal relapses at 1 year and the cumulative probability of dis-
ability progression sustained for at least 12 weeks during 
the 2-year study period. Relapses were deﬁ  ned as any new 
or recurrent neurologic symptoms not associated with fever 
or infection, lasting at least 24 hours, and accompanied 
by new objective neurologic ﬁ  ndings upon examination. 
Disability progression was deﬁ  ned as at least a 1.0-point 
increase in EDSS score from a baseline score 1.0 or a 
1.5-point increase from a baseline score of 0, sustained for 
at least 12 weeks. Secondary 1-year endpoints in both studies 
were the proportion of relapse-free patients, the number of 
new or enlarging T2-hyperintense lesions, and the number 
of gadolinium-enhancing (Gd+) lesions. Secondary 2-year 
endpoints in both studies were the rate of clinical relapses, 
disease progression as measured by the Multiple Sclerosis 
Functional Composite (MSFC) (Rudick et al 1997), the 
number of new T1-hypointense lesions, and the volume of 
T2-hyperintense lesions. Tertiary endpoints in both studies 
included the effects of natalizumab on brain atrophy, HRQoL, 
and visual function.
A total of 942 patients (n = 627 natalizumab; n = 315 
placebo) were enrolled in the AFFIRM study. Baseline demo-
graphics of these patients were similar to those of patients 
with MS who participated in pivotal studies of DMTs (IFNB 
Study Group 1993; Jacobs et al 1996; Johnson et al 1996; 
PRISMS Study Group 1998). The mean age of patients was 
36 years, and the mean number of relapses within the 12 
months before randomization was 1.52. The mean EDSS 
score was 2.3, and the median disease duration was 5 years. 
Patients in the SENTINEL study had similar baseline demo-
graphics and disease characteristics. Of the 1171 patients 
enrolled in SENTINEL (n = 589 natalizumab + interferon 
β-1a; n = 582 placebo + interferon β-1a), the mean age of 
patients was 39 years and the mean number of relapses within 
the 12 months before randomization was 1.47. Mean EDSS 
score was 2.4, and the median disease duration was 7 years 
(Polman et al 2006; Rudick et al 2006).Biologics: Targets & Therapy 2008:2(2) 191
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Clinical outcomes
In the AFFIRM study, natalizumab monotherapy reduced 
the risk of disability progression sustained for 12 weeks over 
2 years by 42% compared with placebo; 17% of patients 
treated with natalizumab experienced disease progression 
compared with 29% of those treated with placebo (hazard 
ratio [HR] = 0.58; 95% conﬁ  dence interval [CI] = 0.43–0.77; 
p 0.001). In a sensitivity analysis, natalizumab reduced the 
risk of progression of disability sustained for 24 weeks over 
2 years by 54% compared with placebo (HR = 0.46; 95% 
CI = 0.33–0.64; p  0.001) (Polman et al 2006). Moreover, 
natalizumab signiﬁ  cantly reduced disability progression as 
measured by the MSFC compared with placebo. A signiﬁ  cant 
difference between the groups in change from baseline in 
MSFC z-score was apparent 12 weeks after start of treatment 
(p  0.001), an effect that was maintained over the 2-year 
study (Balcer et al 2005; Phillips et al 2006).
Natalizumab monotherapy was also associated with sig-
niﬁ  cant improvements in relapse-related outcomes. At 1 year, 
natalizumab reduced the annualized relapse rate by 68% 
compared with placebo (0.26 natalizumab vs 0.81 placebo; 
p  0.001), and this reduction was maintained at 2 years (0.23 
natalizumab vs 0.73 placebo; p  0.001). This result suggests 
that the effect of natalizumab on relapses is substantially 
greater than that of other MS treatments, which have been 
shown to reduce MS relapses over 2 years by up to 34% (IFNB 
Study Group 1993; Jacobs et al 1996; Johnson et al 1996; 
Polman et al 2006; PRISMS Study Group 1998; US FDA 
PCNS Advisory Committee 2006). The proportion of relapse-
free patients was also signiﬁ  cantly greater in the natalizumab 
group compared with the placebo group at 1 year (77% vs 
56%; p  0.001). A similar effect was observed at 2 years 
(67% natalizumab vs 41% placebo; p  0.001) (Polman et al 
2006), which was maintained for up to 3 years in an open-label 
extension study (O’Connor et al 2007).
In the SENTINEL study, natalizumab added to interferon 
β-1a reduced the risk of disability progression sustained for 
12 weeks over 2 years by 24% compared with interferon β-1a 
alone (HR = 0.76; 95% CI = 0.61–0.96; p = 0.02). In a sensi-
tivity analysis of the risk of disability progression sustained 
for 24 weeks, no signiﬁ  cant differences were found between 
the treatment groups (15% for combination therapy vs 18% 
for interferon β-1a alone; HR = 0.82; 95% CI = 0.61–1.09; 
p = 0.17). The addition of natalizumab to interferon β-1a 
signiﬁ  cantly reduced disability progression as measured by 
the MSFC compared with interferon β-1a alone. A signiﬁ  -
cant difference between the groups in change from baseline 
in MSFC z-score was apparent 48 weeks after beginning 
treatment (p  0.005), and this effect was maintained over 
the 2-year study (Data on ﬁ  le, Biogen Idec, Inc. 2007).
As in AFFIRM, natalizumab was also associated with 
signiﬁ  cant reductions in relapse-related outcomes in SENTI-
NEL. The addition of natalizumab to interferon β-1a resulted 
in a 54% reduction in annualized relapse rate at 1 year (0.38 
for interferon β-1a + natalizumab vs 0.82 interferon β-1a 
alone; p  0.001); at 2 years, the relative reduction was 55% 
(0.34 for interferon β-1a + natalizumab vs 0.75 interferon 
β-1a alone; p  0.001). Furthermore, the proportion of 
relapse-free patients at 2 years was 54% in the combination 
therapy group compared with 32% in the interferon β-1a 
alone group (p  0.001) (Rudick et al 2006).
MRI outcomes
In AFFIRM, natalizumab monotherapy caused marked 
reductions in the number and volume of MRI lesions. At 1 
year, the mean number of new or enlarging T2-hyperintense 
lesions was 1.2 in natalizumab-treated patients compared 
with 6.1 in placebo-treated patients (p  0.001). Furthermore, 
natalizumab reduced the mean number of new or enlarging 
T2-hyperintense lesions by 83% over 2 years compared with 
placebo (1.9 vs 11.0; p  0.001). Natalizumab also reduced 
the mean number of Gd+ lesions by 92% at 1 and 2 years 
compared with placebo (p  0.001) (Polman et al 2006) and 
the mean number of new T1-hypointense lesions by 76% 
over 2 years compared with placebo (1.1 vs 4.6; p  0.001) 
(Miller et al 2007). Median T2-hyperintense lesion volume 
was signiﬁ  cantly lower in natalizumab-treated patients com-
pared with placebo-treated patients at 2 years (9175 mm3 vs 
11,137 mm3; p  0.001) (Miller et al 2007).
Brain atrophy can be reliably assessed in patients with 
MS by measuring the brain parenchymal fraction (BPF), 
which is the ratio of brain parenchymal volume to the total 
volume within a smoothed surface contour around the brain 
(Rudick et al 1999). During 2 years of treatment in AFFIRM, 
the change from baseline BPF was similar in natalizumab- 
and placebo-treated patients (mean percent change in 
BPF = –0.80% vs –0.82%; p = 0.822). Although both groups 
exhibited a decrease in BPF from baseline to 1 year, a rela-
tively greater reduction was observed in the natalizumab 
group compared with the placebo group (–0.56% vs –0.40%; 
p = 0.002). In the second year, the mean percent change in 
BPF was signiﬁ  cantly less in the natalizumab group com-
pared with the placebo group (–0.24% vs –0.43%; p = 0.004), 
indicating a signiﬁ  cant slowing of atrophy compared with 
placebo (Miller et al 2007). It is speculated that the greater 
decrease in BPF observed in natalizumab-treated patients Biologics: Targets & Therapy 2008:2(2) 192
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during the ﬁ  rst year of treatment may have been attributable 
to a reduction in inﬂ  ammation and edema, which can cause 
an acute shrinkage of brain tissue known as pseudoatrophy 
(Fisher et al 2006).
In the SENTINEL study, the addition of natalizumab to 
interferon β-1a resulted in signiﬁ  cant reductions in the number 
of MRI lesions. At 1 year, the mean number of new or enlarging 
T2-hyperintense lesions was 0.5 in patients treated with 
natalizumab plus interferon β-1a compared with 2.4 in patients 
treated with interferon β-1a alone (p 0.001). Furthermore, 
the mean number of new or enlarging T2-hyperintense lesions 
was reduced by 83% over 2 years (0.9 interferon β-1a + 
natalizumab vs 5.4 interferon β-1a alone; p  0.001). In 
addition, natalizumab added to interferon β-1a reduced the 
mean number of Gd+ lesions by 88% at 1 year (0.1 interferon 
β-1a + natalizumab vs 0.8 interferon β-1a alone; p  0.001) 
and by 89% at 2 years (0.1 interferon β-1a + natalizumab 
vs 0.9 interferon β-1a alone; p  0.001) compared with 
interferon β-1a alone (Rudick et al 2006). The mean number 
of new T1-hypointense lesions was reduced by 44% over 
2 years (2.3 interferon β-1a + natalizumab vs 4.1 interferon 
β-1a alone; p  0.001). Median T2-hyperintense lesion volume 
was signiﬁ  cantly lower in patients receiving interferon β-1a 
plus natalizumab compared with patients receiving interferon 
β-1a alone at 2 years (5848 mm3 vs 7260 mm3; p  0.001) 
(Data on ﬁ  le, Biogen Idec, Inc. 2007).
Measurements of changes in BPF at 1 and 2 years in 
the SENTINEL study revealed patterns of reduction in 
the interferon β-1a plus natalizumab and interferon β-1a 
alone treatment groups that were similar to those observed 
in the placebo and natalizumab monotherapy groups, 
respectively, in AFFIRM. During 2 years of treatment in 
SENTINEL, the changes in BPF from baseline were similar 
in the natalizumab plus interferon β-1a and interferon β-1a 
alone treatment groups (–0.81% vs –0.82%, p = 0.926). In the 
ﬁ  rst year, however, there was a greater reduction in BPF in the 
natalizumab plus interferon β-1a group (–0.5% vs –0.42%, 
p = 0.058), whereas the reduction in the second year was 
greater in the interferon β-1a alone group (–0.40% vs –0.31%, 
p = 0.020) (Data on ﬁ  le, Biogen Idec, Inc. 2007).
Clinical and MRI efﬁ  cacy in AFFIRM
Post hoc analyses were conducted in patients from the 
AFFIRM study to determine the ability of natalizumab to 
achieve a complete clinical and MRI response. Absence of 
clinical disease activity was deﬁ  ned as no relapses and no 
disability progression, sustained for 12 weeks. Absence of 
MRI disease activity was deﬁ  ned as no Gd+ lesions at 1 and 
2 years and no new or enlarging T2-hyperintense lesions 
during the 2 years. The proportions of patients who were 
free of clinical activity, MRI activity, and a more stringent 
deﬁ  nition of clinical and MRI disease activity over 2 years 
were determined. Signiﬁ  cantly more natalizumab-treated 
patients were free of clinical disease activity (64.3% vs 
38.9%; p  0.0001), MRI disease activity (57.7% vs 14.2%; 
p  0.0001), and both clinical and MRI disease activity (36.7% 
vs 7.2%; p  0.0001) compared with placebo-treated patients 
over the 2 years of the study (Havrdova et al 2007).
Clinical and MRI efﬁ  cacy in patients 
with highly active MS
Post hoc analyses of patients with highly active relapsing MS 
( 2 relapses in the year prior to study entry and  1 Gd+ 
lesion on T1-weighted MRI at study entry) were performed 
for AFFIRM and SENTINEL. In AFFIRM patients with 
highly active disease (n = 148 natalizumab; n = 61 placebo), 
natalizumab monotherapy reduced the risk of disability pro-
gression sustained for 12 weeks by 53% (HR = 0.47; 95% 
CI = 0.24–0.93; p = 0.029) and progression sustained for 24 
weeks by 64% (HR = 0.36; 95% CI = 0.17–0.76; p = 0.008) 
compared with placebo. In addition, natalizumab reduced the 
2-year annualized relapse rate by 81% compared with placebo 
(0.28 vs 1.46, respectively; p  0.001) in these patients. 
Furthermore, signiﬁ  cant improvements on all MRI outcomes 
were observed with natalizumab compared with placebo in 
patients with highly active disease (Data on ﬁ  le, Biogen Idec, 
Inc. 2007; European Union TYSABRI SmPC 2006).
In SENTINEL patients with highly active disease (n = 74 
interferon β-1a + natalizumab; n = 95 interferon β-1a alone), 
the addition of natalizumab to interferon β-1a reduced the 
risk of disability progression sustained for 12 weeks by 61% 
(HR = 0.39; 95% CI = 0.21, 0.74; p = 0.004) and sustained 
for 24 weeks by 58% (HR = 0.42, CI = 0.19, 0.95; p = 0.038) 
compared with interferon β-1a alone. The addition of natali-
zumab to interferon β-1a also led to a 76% reduction in the 
2-year annualized relapse rate compared with interferon β-1a 
alone (0.28 vs 1.16; p  0.001). Furthermore, signiﬁ  cant 
improvements on all MRI outcomes were observed in the 
interferon β-1a plus natalizumab group compared with the 
interferon β-1a group in highly active patients (Data on ﬁ  le, 
Biogen Idec, Inc. 2007).
HRQoL
The chronic symptoms of MS interfere with activities of daily 
living, resulting in signiﬁ  cantly reduced HRQoL. In contrast to 
the clinical and MRI outcomes that are measured by physicians, Biologics: Targets & Therapy 2008:2(2) 193
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HRQoL endpoints provide an assessment of a therapy on 
domains regarded by patients as key factors in determining their 
overall health status. The majority of phase 3 studies in patients 
with MS lack HRQoL measures; thus, a rigorous assessment of 
HRQoL was performed in AFFIRM and SENTINEL. HRQoL 
was evaluated using the Short Form-36 (SF-36) (Ware et al 
1992) and the visual analog scale (VAS), a subjective global 
assessment of well-being. To date, the SF-36 has not been used 
to assess HRQoL in pivotal trials of other MS treatments. In 
AFFRIM and SENTINEL it was administered as a part of the 
Multiple Sclerosis Quality of Life Inventory (Consortium of 
Multiple Sclerosis Centers 1997). Two summary scores from 
the SF-36 were calculated: the Physical Component Summary 
(PCS) and the Mental Component Summary (MCS). The SF-
36 and the VAS were administered to patients enrolled in both 
AFFIRM and SENTINEL at baseline and at weeks 24, 52, and 
104 (Rudick et al 2007).
Data from AFFIRM and SENTINEL (N = 2113) were 
combined to evaluate the burden of MS on HRQoL. The 
baseline mean PCS and MCS scores were 43.2 ± 0.4 and 
47.0 ± 0.5, respectively, and were signiﬁ  cantly lower than 
the mean scores for the general US population (50.0) (Rudick 
et al 2007). Furthermore, at study entry, the PCS scores for 
patients with an EDSS score 2.0 were signiﬁ  cantly lower 
than for those patients with an EDSS score of 0 (p  0.005) 
(Rudick et al 2007). Similarly, VAS scores for patients 
with EDSS scores 1.5 were signiﬁ  cantly lower compared 
with those for patients with an EDSS score of 0 (p  0.05). 
Taken together, these data provide evidence that HRQoL is 
signiﬁ  cantly reduced in patients with relapsing MS.
In AFFIRM, natalizumab monotherapy was associated 
with signiﬁ  cant improvements in PCS (p = 0.003) and MCS 
(p = 0.011) scores at week 104 (Figure 1). In fact, changes 
from baseline in PCS scores were signiﬁ  cantly higher at 
weeks 24, 52, and 104 compared with placebo. In SENTINEL, 
changes from baseline in PCS scores for patients treated with 
interferon β-1a plus natalizumab were signiﬁ  cantly higher at 
weeks 52 (p = 0.014) and 104 (p  0.001) compared with 
scores for patients treated with interferon β-1a alone (Rudick 
et al 2007). Additionally, a greater percentage of natalizumab-
treated patients improved and a lower percentage worsened 
by a clinically important amount (deﬁ  ned as a 0.5 standard 
deviation change from baseline to week 104 in PCS and MCS 
scores) compared with placebo- or interferon β-1a–treated 
patients in both studies (Rudick et al 2007). Findings from the 
subject global assessment of well-being were similar to those 
from the SF-36. Changes from baseline in VAS scores for 
patients treated with natalizumab monotherapy were greater 
than those for patients treated with placebo at weeks 52 (p = 
0.042) and 104 (p = 0.007) (Rudick et al 2007).
Visual function
Visual function is an important measure of neurologic impair-
ment in patients with relapsing MS. For example, remitting 
episodes of acute optic neuritis can inﬂ  uence the overall 
visual function of a patient. Thus, prespeciﬁ  ed analyses were 
performed in AFFIRM and SENTINEL to determine the 
effect of natalizumab on visual function (Balcer et al 2007). 
Visual acuity was measured using the Sloan letter chart at 3 
contrast levels: 100% (high-contrast), 2.5% (low-contrast), 
and 1.25% (low-contrast). Visual function testing was per-
formed every 12 weeks using a standardized protocol based 
on visual acuity testing methods from the Early Treatment 
Diabetic Retinopathy Study (Balcer et al 2007). Sloan chart 
scores for each contrast level were calculated based on the 
number of letters correctly identiﬁ  ed by the patient. The 
cumulative probability of clinically signiﬁ  cant worsening 
of visual function, deﬁ  ned as 2-line (10-letter) reductions in 
Sloan chart scores persisting over 12 weeks, was determined 
using Kaplan-Meier analysis (Balcer et al 2007).
When low-contrast Sloan charts were used, patients 
treated with natalizumab had lower cumulative probabili-
ties of sustained clinically signiﬁ  cant worsening of visual 
function compared with placebo or interferon β-1a alone. In 
AFFIRM, natalizumab reduced the risk of sustained clinically 
signiﬁ  cant worsening of visual function by 47% (HR = 0.53; 
95% CI = 0.36–0.76; p  0.001) at the 2.5% contrast level 
and by 35% (HR = 0.65; 95% CI = 0.47–0.90; p = 0.008) at 
the 1.25% contrast level compared with placebo (Figure 2) 
(Balcer et al 2007).
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Calabresi PA, et al. 2007. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 68:1299–304. Copyright © 2007, with permission from 
Lippincott, Williams & Wilkins.Biologics: Targets & Therapy 2008:2(2) 195
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In SENTINEL, the cumulative probability of sustained 
clinically signiﬁ  cant worsening of visual function was lower 
for both low-contrast Sloan charts in patients treated with inter-
feron β-1a plus natalizumab compared with patients treated 
with interferon β-1a alone. However, clinically signiﬁ  cant 
differences were demonstrated only at the 1.25% contrast 
level (HR = 0.72; 95% CI = 0.54–0.98; p = 0.038). In addition, 
differences between treatment groups occurred later over the 
2-year treatment period. These ﬁ  ndings were attributed to the 
use of an active-comparator treatment arm, which may require 
longer follow-up periods and more sensitive treatment mea-
sures to detect treatment effects (Balcer et al 2007).
Immunogenicity of natalizumab
Antibody formation is an expected response to treatment with 
therapeutic proteins, and the formation of such antibodies 
has been demonstrated to reduce the efﬁ  cacy of the product 
(Schellekens and Casadevall 2004). In the AFFIRM and 
SENTINEL studies, patients were tested for the development 
of anti-natalizumab antibodies every 12 weeks throughout 
the study. Serum concentrations of anti-natalizumab antibod-
ies were determined by an enzyme-linked immunosorbent 
assay, and patients were deﬁ  ned as being antibody nega-
tive ( 0.5 μg/mL at all time points), transiently positive 
( 0.5 μg/mL at a single time point), or persistently positive 
( 0.5 μg/mL at 2 or more time points at least 6 weeks apart) 
(Calabresi et al 2007).
In AFFIRM, 57 natalizumab patients (9%) developed 
anti-natalizumab antibodies; 3% (n = 20) were transiently 
positive, and 6% (n = 37) were persistently positive. 
During SENTINEL, 12% of patients (n = 70) developed 
anti-natalizumab antibodies; 5% (n = 32) were transiently 
positive, and 6% (n = 38) were persistently positive (Calabresi 
et al 2007). Most patients who developed anti-natalizumab 
antibodies did so within 12 weeks of starting natalizumab 
treatment (88% AFFIRM; 96% SENTINEL) (Calabresi et al 
2007). Notably, the presence of anti-natalizumab antibodies 
was associated with a reduction in trough serum natalizumab 
concentrations (Calabresi et al 2007). Persistent antibodies 
were associated with a loss of efﬁ  cacy as measured by clinical 
and MRI outcomes. In contrast, transiently positive patients 
experienced delayed therapeutic effects of natalizumab, 
but full efﬁ  cacy was eventually achieved with continued 
treatment (Calabresi et al 2007).
Tolerability and safety
Overall, natalizumab was well tolerated in the AFFIRM and 
SENTINEL studies. In AFFIRM, infusion reactions, deﬁ  ned 
as any event occurring within 2 hours of the start of infusion, 
occurred in 24% of natalizumab-treated patients compared 
with 18% of placebo patients (p = 0.04) (Polman et al 2006). 
Similarly, in SENTINEL, the incidence of infusion reactions 
was 24% in the interferon β-1a plus natalizumab group and 
20% in the interferon β-1a alone group (p = 0.11). The most 
common of these reactions was headache, which did not 
usually result in discontinuation of natalizumab treatment. 
Hypersensitivity reactions were deﬁ  ned as reports of hyper-
sensitivity, allergic reaction, or anaphylactic/anaphylactoid 
reactions and any reports of urticaria, allergic dermatitis, or 
hives. In AFFIRM, the incidence of hypersensitivity reac-
tions associated with natalizumab was 4% and the incidence 
of anaphylactic/anaphylactoid reactions was 0.8% (Polman 
et al 2006). In SENTINEL, 11 patients (1.9%) receiving 
combination therapy experienced a hypersensitivity reaction, 
and there were no reports of anaphylactic or anaphylactoid 
reactions associated with natalizumab (Rudick et al 2006). 
An evaluation of hypersensitivity reactions according to 
anti-natalizumab antibody status revealed that 46% of 37 
persistently positive patients and 15% of 20 transiently posi-
tive patients in AFFIRM experienced a hypersensitivity reac-
tion. The corresponding values for patients in SENTINEL 
were 21% of 38 persistently positive patients and none of 32 
transiently positive patients (Calabresi et al 2007). Patients 
who experienced hypersensitivity reactions while receiving 
natalizumab during the studies discontinued treatment.
As previously stated, non-hypersensitivity–mediated 
infusion reactions did not necessitate discontinuation of 
natalizumab therapy in AFFIRM or SENTINEL. However, 
infusion reactions that occurred over multiple natalizumab 
infusions were associated with persistent positivity for 
anti-natalizumab antibodies. Therefore, testing for anti-
natalizumab antibodies should be considered in the setting 
of recurrent infusion-related symptoms. Two consecutive 
positive blood samples separated by 2–3 months after at least 
6 months’ treatment conﬁ  rm persistent antibody-positive 
status. Discontinuation of natalizumab should be strongly 
considered once persistent positivity is conﬁ  rmed.
Generally, few differences in adverse event proﬁ  les were 
observed between natalizumab and placebo or interferon β-1a 
groups in AFFIRM and SENTINEL. Common adverse events 
were generally mild and included headache, fatigue, urinary 
tract infections, and arthralgia (Tysabri® package insert 
2007). In AFFIRM, patients treated with natalizumab mono-
therapy experienced more fatigue (27% vs 21%; p = 0.048) 
and allergic reactions (9% vs 4%; p = 0.012) compared with 
those who received placebo (Polman et al 2006). During the Biologics: Targets & Therapy 2008:2(2) 196
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SENTINEL study, patients treated with natalizumab plus 
interferon β-1a experienced signiﬁ  cantly more pharyngitis 
(7% vs 4%; p  0.05), anxiety (12% vs 8%; p  0.01), sinus 
congestion (6% vs 3%; p  0.01), and peripheral edema (5% 
vs 1%; p  0.001) compared with patients who received 
interferon β-1a alone (Rudick et al 2006). In both studies, 
the incidence of infection was similar between the treatment 
groups (AFFIRM, 79% in natalizumab and placebo groups 
[Figure 3]; SENTINEL, 83% in the interferon β-1a + natali-
zumab group vs 81% in interferon β-1a alone) (Polman et al 
2006; Rudick et al 2006).
Laboratory testing has shown that natalizumab causes 
reversible elevations in circulating lymphocytes, monocytes, 
eosinophils, basophils and nucleated red blood cells (but not 
neutrophils). Moreover, rare cases of clinically signiﬁ  cant 
hepatoxicity have been reported in the postmarketing setting 
(Tysabri® package insert 2007). Regular laboratory monitoring 
during natalizumab treatment is not considered necessary.
In February 2005, commercial and clinical trial dosing 
of natalizumab was voluntarily suspended after 2 reports of 
progressive multifocal leukoencephalopathy (PML), a seri-
ous, sometimes fatal, demyelinating disease of the CNS that 
results from reactivation of the latent JC virus and that usually 
occurs in immunocompromised patients (Major et al 1992). 
Both patients had received natalizumab plus interferon β-1a 
in SENTINEL (Kleinschmidt-DeMasters and Tyler 2005; 
Langer-Gould et al 2005). A third case of PML was retro-
spectively identiﬁ  ed in a patient who was treated with natali-
zumab for Crohn’s disease in a clinical study (Van Assche 
et al 2005). Subsequent to these reports of PML, an extensive 
safety evaluation revealed no additional cases of PML among 
3116 patients who received natalizumab in clinical studies. 
The risk of developing PML associated with natalizumab use 
was determined to be 1 in 1000 patients (95% CI = 0.2, 2.8 
in 1000 patients) over 17.9 months of treatment (Yousry et al 
2006). Natalizumab was reintroduced in the United States and 
approved in the European Union in June 2006.
To better assess the safety proﬁ  le of natalizumab, a com-
prehensive risk management plan that includes the Tysabri® 
Outreach: Unified Commitment to Health (TOUCH™) 
Prescribing Program and the Tysabri® Global Observation 
Program in Safety (TYGRIS) observational cohort study 
was developed. The TOUCH™ Prescribing Program is a 
mandatory prescribing program in the United States. All 
physicians, infusion sites, and patients are required to enroll 
before natalizumab treatment is initiated, and reauthoriza-
tion is required every 6 months. The objectives of TOUCH™ 
are to ensure appropriate and informed use of natalizumab, 
assess the incidence of serious opportunistic infections, 
including PML, in patients treated with natalizumab, and 
monitor natalizumab-treated patients for signs and symptoms 
of PML. TYGRIS is a voluntary global observational study 
designed to investigate the long-term safety of natalizumab 
in the clinical practice setting. A recent update of safety 
data collected from the TOUCH™ and TYGRIS programs 
showed that the safety proﬁ  le of natalizumab was consistent 
with that seen in earlier clinical studies (Panzara et al 2007). 
Global utilization data released in January, 2008, indicate 
that approximately 30,900 patients have been treated with 
natalizumab in the combined clinical trial and postmarket-
ing settings, and of these patients, approximately 6,300 have 
received natalizumab for at least 1 year (unpublished data 
on ﬁ  le, Biogen Idec). In addition to TOUCH™ and TYGRIS, 
the Tysabri® Observational Program in Europe will provide 
further insight into the long-term effects of natalizumab. 
Currently, several initiatives to better understand PML and 
its management in the context of natalizumab therapy are 
being planned or conducted.
Patient selection and PML 
diagnostic algorithm
A recent publication by a panel of experts in neurology, neu-
roradiology, and PML provides guidelines to help with the 
selection of appropriate candidates for natalizumab therapy 
and with the diagnosis of suspected PML (Kappos et al 2007). 
The article recommends that patients who have received 
prior treatment with immunosuppressants or antineoplastic 
agents should be carefully assessed for ongoing immunosup-
pression before initiating natalizumab. Recommendations 
based on clinical and laboratory markers to help identify 
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immunocompetence in patients who have been exposed to 
immunosuppressive therapy have been published separately 
by Gold and colleagues (Gold et al 2007). A pretreatment 
cranial MRI scan is also recommended for all patients within 
3 months of commencing natalizumab therapy to help in 
the assessment of subsequent new or worsening neurologic 
symptoms that may develop during treatment.
It is further recommended in the article that new or 
worsening neurological symptoms should lead to immediate 
suspension of natalizumab dosing and completion of a thor-
ough neurologic assessment (Figure 4). Continued suspicion 
of PML after the neurologic assessment warrants a cranial 
MRI scan with gadolinium enhancement for comparison with 
the baseline pretreatment MRI scan and, if PML is still a 
concern, cerebrospinal ﬂ  uid (CSF) testing for JC virus (JCV) 
DNA is recommended. However, CSF is usually negative 
for JCV DNA in the early stages of PML. Therefore, if the 
disease is still suspected after a negative CSF test, diagnostic 
work up should continue and natalizumab treatment should 
not be restarted. Clinical and MRI characteristics that may 
help to distinguish between PML and MS are presented in 
Table 1 (Kappos et al 2007).
At present, there is no proven treatment for PML. How-
ever, experience with PML in organ transplant recipients 
and patients with HIV strongly suggests that reconstitution 
of the immune system is associated with a better prognosis 
(Clifford et al 1999; Crowder et al 2005; Shitrit et al 2005). 
A recent study by Khatri et al provided preliminary evidence 
that accelerated removal of natalizumab from circulation via 
plasma exchange may be a method to reconstitute the immune 
system in natalizumab-treated patients who develop PML 
(Khatri et al 2007). However, because plasma exchange has 
not been speciﬁ  cally tested in natalizumab-treated patients with 
PML, the true efﬁ  cacy of the procedure remains unknown.
Prescribing considerations
Natalizumab is indicated as monotherapy for the treat-
ment of relapsing MS and is generally recommended 
for patients who have had an inadequate response to, or 
are unable to tolerate, alternate MS therapies. However, 
prescribing information in the United States does not 
preclude the use of natalizumab as a first-line agent for 
the treatment of relapsing MS (Tysabri® package insert 
2007). In the European Union, natalizumab is approved 
as a first-line agent for patients with highly active disease 
(2 disabling relapses in the previous year and 1 Gd+ 
lesion on MRI) and as a second-line therapy in patients 
who have experienced 1 relapse in the previous year 
and 9 T2 lesions or 1 Gd+ lesion while receiving 
interferon β (European Agency for the Evaluation of 
Medicinal Products 2006).
Summary
Natalizumab is the ﬁ  rst α4-integrin receptor antagonist avail-
able for the treatment of relapsing MS. Through its proposed 
mechanism of action, natalizumab provides evidence for 
Dosing may be resumed 
Clinical assessment of new neurological symptoms 
if suggestive of non–MS-related disease 
Suspend dosing 
MRI assessment 
PML unlikely 
CSF assessment 
Treat as PML  Repeat assessment 
JCV not detected 
and low clinical suspicion 
JCV detected  JCV not detected 
and high clinical suspicion 
Cannot exclude PML 
a
Figure 4 Diagnostic algorithm for patients with suspected progressive multifocal leukoencephalopathy (PML). Reprinted from Kappos L, Bates D, Hartung H-P, et al. 2007. Natalizumab 
treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol, 6:431–41. Copyright © 2007, with permission from Elsevier.
aIf PML is suspected on the basis of clinical presentation and MRI is not readily available, CSF assessment to exclude PML should be considered before MRI.
Abbreviations: CSF, cerebrospinal ﬂ  uid; JCV, polyomavirus JC virus; MRI, magnetic resonance imaging; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy.Biologics: Targets & Therapy 2008:2(2) 198
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the role of circulating mononuclear leukocytes in disease 
pathogenesis. Natalizumab has demonstrated signiﬁ  cant 
clinical and MRI efﬁ  cacy in patients with relapsing MS. 
Natalizumab monotherapy was associated with signiﬁ  cant 
reductions in annualized relapse rate, the risk of sustained 
disability progression, and the number and volume of MRI 
lesions. Additional data have shown that natalizumab reduces 
the risk of developing sustained visual loss and is associated 
with improvements in HRQoL. Natalizumab demonstrated 
a favorable tolerability proﬁ  le in phase 3 studies; a low 
incidence of persistent anti-natalizumab antibody develop-
ment and hypersensitivity reactions was observed, and most 
natalizumab-associated adverse events were generally mild. 
The risk of PML with natalizumab use is small, but appro-
priate patient selection requires an individual assessment of 
beneﬁ  t-risk and careful monitoring.
With its demonstrated efficacy on a number of 
physician- and patient-measured outcomes, natalizumab 
represents a major advance in the treatment of relapsing MS. 
The available data support a favorable beneﬁ  t-risk proﬁ  le 
of natalizumab. Ongoing research and clinical experience 
will expand current knowledge regarding long-term efﬁ  cacy 
and safety.
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